Wall Street Journal: Vaunted Ebola Vaccine Faces Questions
“…In December, doctors from the World Health Organization, Doctors Without Borders, and other groups reported in the British medical journal The Lancet that a vaccine from Merck & Co. and NewLink Genetics Corp. tested during the outbreak proved to be 100 percent effective at preventing people from contracting the hemorrhagic fever once the vaccine’s protection kicked in. Now there are questions about that claim. A panel of scientists from the esteemed U.S. National Academy of Medicine has challenged the methodology of that 4,160-patient trial in the African nation of Guinea. They conclude the vaccine ‘most likely provides some protection to recipients’ but that protection ‘could in reality be quite low’…” (Burton/Hackman, 4/24).